Weekly Research Analysts’ Ratings Changes for BAVARIAN NORDIC/S (BVNRY)

BAVARIAN NORDIC/S (OTCMKTS: BVNRY) recently received a number of ratings updates from brokerages and research firms:

  • 10/14/2019 – BAVARIAN NORDIC/S was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Bavarian Nordic A/S is a biotechnology company. It focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. The company’s product pipeline consists of IMVAMUNE(R), PROSTVAC (R), MVA-BN Brachyury, CV-301, MVA-BN Filo which are in clinical trial stage. Bavarian Nordic A/S is headquartered in Kvistgaard, Denmark. “
  • 10/7/2019 – BAVARIAN NORDIC/S was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Bavarian Nordic A/S is a biotechnology company. It focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. The company’s product pipeline consists of IMVAMUNE(R), PROSTVAC (R), MVA-BN Brachyury, CV-301, MVA-BN Filo which are in clinical trial stage. Bavarian Nordic A/S is headquartered in Kvistgaard, Denmark. “
  • 9/30/2019 – BAVARIAN NORDIC/S was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Bavarian Nordic A/S is a biotechnology company. It focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. The company’s product pipeline consists of IMVAMUNE(R), PROSTVAC (R), MVA-BN Brachyury, CV-301, MVA-BN Filo which are in clinical trial stage. Bavarian Nordic A/S is headquartered in Kvistgaard, Denmark. “
  • 9/24/2019 – BAVARIAN NORDIC/S was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Bavarian Nordic A/S is a biotechnology company. It focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. The company’s product pipeline consists of IMVAMUNE(R), PROSTVAC (R), MVA-BN Brachyury, CV-301, MVA-BN Filo which are in clinical trial stage. Bavarian Nordic A/S is headquartered in Kvistgaard, Denmark. “
  • 9/16/2019 – BAVARIAN NORDIC/S was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Bavarian Nordic A/S is a biotechnology company. It focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. The company’s product pipeline consists of IMVAMUNE(R), PROSTVAC (R), MVA-BN Brachyury, CV-301, MVA-BN Filo which are in clinical trial stage. Bavarian Nordic A/S is headquartered in Kvistgaard, Denmark. “
  • 9/10/2019 – BAVARIAN NORDIC/S was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Bavarian Nordic A/S is a biotechnology company. It focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. The company’s product pipeline consists of IMVAMUNE(R), PROSTVAC (R), MVA-BN Brachyury, CV-301, MVA-BN Filo which are in clinical trial stage. Bavarian Nordic A/S is headquartered in Kvistgaard, Denmark. “
  • 9/3/2019 – BAVARIAN NORDIC/S was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Bavarian Nordic A/S is a biotechnology company. It focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. The company’s product pipeline consists of IMVAMUNE(R), PROSTVAC (R), MVA-BN Brachyury, CV-301, MVA-BN Filo which are in clinical trial stage. Bavarian Nordic A/S is headquartered in Kvistgaard, Denmark. “
  • 8/28/2019 – BAVARIAN NORDIC/S was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Bavarian Nordic A/S is a biotechnology company. It focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. The company’s product pipeline consists of IMVAMUNE(R), PROSTVAC (R), MVA-BN Brachyury, CV-301, MVA-BN Filo which are in clinical trial stage. Bavarian Nordic A/S is headquartered in Kvistgaard, Denmark. “
  • 8/21/2019 – BAVARIAN NORDIC/S was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Bavarian Nordic A/S is a biotechnology company. It focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. The company’s product pipeline consists of IMVAMUNE(R), PROSTVAC (R), MVA-BN Brachyury, CV-301, MVA-BN Filo which are in clinical trial stage. Bavarian Nordic A/S is headquartered in Kvistgaard, Denmark. “

Shares of BVNRY stock remained flat at $$8.31 during trading hours on Tuesday. The stock has a fifty day simple moving average of $8.83 and a two-hundred day simple moving average of $7.99. The stock has a market cap of $805.49 million, a P/E ratio of -14.08 and a beta of 0.61. BAVARIAN NORDIC/S has a twelve month low of $5.92 and a twelve month high of $10.93. The company has a current ratio of 7.93, a quick ratio of 7.52 and a debt-to-equity ratio of 0.23.

BAVARIAN NORDIC/S (OTCMKTS:BVNRY) last issued its earnings results on Thursday, August 15th. The company reported ($0.16) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.13) by ($0.03). The business had revenue of $15.26 million during the quarter, compared to analyst estimates of $19.80 million. BAVARIAN NORDIC/S had a negative net margin of 42.42% and a negative return on equity of 12.47%. Equities analysts predict that BAVARIAN NORDIC/S will post -0.56 EPS for the current fiscal year.

Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of cancer immunotherapies and vaccines for infectious diseases. The company markets non-replicating smallpox vaccine under the IMVAMUNE and IMVANEX names. It is also developing MVA-BN RSV, which is in Phase II clinical trials development stage for the prevention of respiratory syncytial virus; MVA-BN Filo that is in Phase III clinical trials for the treatment of Ebola and Marburg; and MVA-BN HPV that is in Phase I/IIa clinical trials to treat human papillomavirus.

Featured Story: What is the return on assets formula?

Receive News & Ratings for BAVARIAN NORDIC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BAVARIAN NORDIC/S and related companies with MarketBeat.com's FREE daily email newsletter.